Androisoxazole (brand names Androxan, Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy.[1][2][3][4] It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring,[4] and is also related to furazabol, prostanozol, and danazol.
Clinical data | |
---|---|
Trade names | Androxan, Neo-Ponden, Neo-Pondus |
Other names | 17α-Methyl-5α-androstano[3,2-c]isoxazol-17β-ol |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C21H31NO2 |
Molar mass | 329.484 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |